Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
EBS-LASV
- Development stage
- Unknown
- Lead developer
- Aurobindo Pharma
- Modality
- Vaccines & Immunotherapeutics
- Administration
- Intramuscular
01
Overview
**EBS-LASV** is a monovalent, live-attenuated recombinant vesicular stomatitis virus vaccine candidate for prevention of Lassa fever. It uses the VesiculoVax platform and encodes the Lassa virus surface glycoprotein complex, with attenuation engineered through VSV nucleoprotein gene shuffling and deletion of the native VSV glycoprotein gene. The vaccine is intended to induce protective immune responses, including neutralizing antibodies, against Lassa virus glycoprotein. The program originated at Profectus BioSciences, was subsequently advanced by Emergent BioSolutions with CEPI support, and has entered Phase 1 clinical evaluation in healthy adults in Ghana. ([mdpi.com](https://www.mdpi.com/2076-393X/12/8/858))
- Other names
- VesiculoVax-vectored Lassa vaccine
02
Targets
GPC (Lassa virus glycoprotein complex)
Beyond the preview
Go deeper on EBS-LASV.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on EBS-LASV.